---
title: "ARGX: $2.2B acquisition adds FB102, advancing autoimmune pipeline and Vision 2030 goals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293927936.md"
description: "The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.Original document: argenx SE [ARGX] Slides Release — Jul. 27 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-27T11:54:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293927936.md)
  - [en](https://longbridge.com/en/news/293927936.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293927936.md)
---

# ARGX: $2.2B acquisition adds FB102, advancing autoimmune pipeline and Vision 2030 goals

The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.

Original document: argenx SE \[ARGX\] Slides Release — Jul. 27 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md)
- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3](https://longbridge.com/en/news/296061848.md)
- [Toth Financial Advisory Corp Boosts Stock Holdings in argenex SE $ARGX](https://longbridge.com/en/news/295778295.md)
- [$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296119451.md)
- [Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint](https://longbridge.com/en/news/296059044.md)
- [These Analysts Boost Their Forecasts On Argenx](https://longbridge.com/en/news/296226998.md)